MedImmune High Court Decision Could Carry Extra Weight For Generic Firms
Executive Summary
The U.S. Supreme Court's refusal to hear a case brought by Apotex against Pfizer could increase the importance of its upcoming decision in MedImmune v. Genentech to provide clarity on exclusivity forfeiture provisions for generic firms
You may also be interested in...
Declaratory Judgments For Generic Firms May Be Easier After MedImmune Case
The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could be in a case brought by Teva against Novartis regarding Famvir
Declaratory Judgments For Generic Firms May Be Easier After MedImmune Case
The first application of a recent Supreme Court decision which appears to ease the way for declaratory judgment actions by ANDA filers could be in a case brought by Teva against Novartis regarding Famvir
Generic Exclusivity Forfeiture Provision Hits Snag In Courts; FTC Wants Fix
A key provision of the Medicare Modernization Act's forfeiture provision for ANDA filers' 180-day exclusivity could be moot if courts continue to refuse to hear petitions by generic companies for declaratory judgments
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: